Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Biosimilar Monoclonal Antibodies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biosimilar Monoclonal Antibodies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biosimilar Monoclonal Antibodies Overall Market Size
2.1 Global Biosimilar Monoclonal Antibodies Market Size: 2022 VS 2029
2.2 Global Biosimilar Monoclonal Antibodies Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Biosimilar Monoclonal Antibodies Sales: 2018-2029
3 Company Landscape
3.1 Top Biosimilar Monoclonal Antibodies Players in Global Market
3.2 Top Global Biosimilar Monoclonal Antibodies Companies Ranked by Revenue
3.3 Global Biosimilar Monoclonal Antibodies Revenue by Companies
3.4 Global Biosimilar Monoclonal Antibodies Sales by Companies
3.5 Global Biosimilar Monoclonal Antibodies Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Biosimilar Monoclonal Antibodies Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Biosimilar Monoclonal Antibodies Product Type
3.8 Tier 1, Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Players in Global Market
3.8.1 List of Global Tier 1 Biosimilar Monoclonal Antibodies Companies
3.8.2 List of Global Tier 2 and Tier 3 Biosimilar Monoclonal Antibodies Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Biosimilar Monoclonal Antibodies Market Size Markets, 2022 & 2029
4.1.2 Infliximab
4.1.3 Rituximab
4.1.4 Trastuzumab
4.1.5 Adalimumab
4.1.6 Other
4.2 By Type - Global Biosimilar Monoclonal Antibodies Revenue & Forecasts
4.2.1 By Type - Global Biosimilar Monoclonal Antibodies Revenue, 2018-2023
4.2.2 By Type - Global Biosimilar Monoclonal Antibodies Revenue, 2024-2029
4.2.3 By Type - Global Biosimilar Monoclonal Antibodies Revenue Market Share, 2018-2029
4.3 By Type - Global Biosimilar Monoclonal Antibodies Sales & Forecasts
4.3.1 By Type - Global Biosimilar Monoclonal Antibodies Sales, 2018-2023
4.3.2 By Type - Global Biosimilar Monoclonal Antibodies Sales, 2024-2029
4.3.3 By Type - Global Biosimilar Monoclonal Antibodies Sales Market Share, 2018-2029
4.4 By Type - Global Biosimilar Monoclonal Antibodies Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Biosimilar Monoclonal Antibodies Market Size, 2022 & 2029
5.1.2 Oncology
5.1.3 Autoimmune Disease
5.1.4 Other
5.2 By Application - Global Biosimilar Monoclonal Antibodies Revenue & Forecasts
5.2.1 By Application - Global Biosimilar Monoclonal Antibodies Revenue, 2018-2023
5.2.2 By Application - Global Biosimilar Monoclonal Antibodies Revenue, 2024-2029
5.2.3 By Application - Global Biosimilar Monoclonal Antibodies Revenue Market Share, 2018-2029
5.3 By Application - Global Biosimilar Monoclonal Antibodies Sales & Forecasts
5.3.1 By Application - Global Biosimilar Monoclonal Antibodies Sales, 2018-2023
5.3.2 By Application - Global Biosimilar Monoclonal Antibodies Sales, 2024-2029
5.3.3 By Application - Global Biosimilar Monoclonal Antibodies Sales Market Share, 2018-2029
5.4 By Application - Global Biosimilar Monoclonal Antibodies Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Biosimilar Monoclonal Antibodies Market Size, 2022 & 2029
6.2 By Region - Global Biosimilar Monoclonal Antibodies Revenue & Forecasts
6.2.1 By Region - Global Biosimilar Monoclonal Antibodies Revenue, 2018-2023
6.2.2 By Region - Global Biosimilar Monoclonal Antibodies Revenue, 2024-2029
6.2.3 By Region - Global Biosimilar Monoclonal Antibodies Revenue Market Share, 2018-2029
6.3 By Region - Global Biosimilar Monoclonal Antibodies Sales & Forecasts
6.3.1 By Region - Global Biosimilar Monoclonal Antibodies Sales, 2018-2023
6.3.2 By Region - Global Biosimilar Monoclonal Antibodies Sales, 2024-2029
6.3.3 By Region - Global Biosimilar Monoclonal Antibodies Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Biosimilar Monoclonal Antibodies Revenue, 2018-2029
6.4.2 By Country - North America Biosimilar Monoclonal Antibodies Sales, 2018-2029
6.4.3 US Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.4.4 Canada Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.4.5 Mexico Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Biosimilar Monoclonal Antibodies Revenue, 2018-2029
6.5.2 By Country - Europe Biosimilar Monoclonal Antibodies Sales, 2018-2029
6.5.3 Germany Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5.4 France Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5.5 U.K. Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5.6 Italy Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5.7 Russia Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5.8 Nordic Countries Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.5.9 Benelux Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Biosimilar Monoclonal Antibodies Revenue, 2018-2029
6.6.2 By Region - Asia Biosimilar Monoclonal Antibodies Sales, 2018-2029
6.6.3 China Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.6.4 Japan Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.6.5 South Korea Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.6.6 Southeast Asia Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.6.7 India Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Biosimilar Monoclonal Antibodies Revenue, 2018-2029
6.7.2 By Country - South America Biosimilar Monoclonal Antibodies Sales, 2018-2029
6.7.3 Brazil Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.7.4 Argentina Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Biosimilar Monoclonal Antibodies Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Biosimilar Monoclonal Antibodies Sales, 2018-2029
6.8.3 Turkey Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.8.4 Israel Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.8.5 Saudi Arabia Biosimilar Monoclonal Antibodies Market Size, 2018-2029
6.8.6 UAE Biosimilar Monoclonal Antibodies Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Celltrion
7.1.1 Celltrion Company Summary
7.1.2 Celltrion Business Overview
7.1.3 Celltrion Biosimilar Monoclonal Antibodies Major Product Offerings
7.1.4 Celltrion Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.1.5 Celltrion Key News & Latest Developments
7.2 Pfizer (Hospira)
7.2.1 Pfizer (Hospira) Company Summary
7.2.2 Pfizer (Hospira) Business Overview
7.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Major Product Offerings
7.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer (Hospira) Key News & Latest Developments
7.3 3SBIO
7.3.1 3SBIO Company Summary
7.3.2 3SBIO Business Overview
7.3.3 3SBIO Biosimilar Monoclonal Antibodies Major Product Offerings
7.3.4 3SBIO Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.3.5 3SBIO Key News & Latest Developments
7.4 Novartis (Sandoz)
7.4.1 Novartis (Sandoz) Company Summary
7.4.2 Novartis (Sandoz) Business Overview
7.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Major Product Offerings
7.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.4.5 Novartis (Sandoz) Key News & Latest Developments
7.5 Dr Reddy?s
7.5.1 Dr Reddy?s Company Summary
7.5.2 Dr Reddy?s Business Overview
7.5.3 Dr Reddy?s Biosimilar Monoclonal Antibodies Major Product Offerings
7.5.4 Dr Reddy?s Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.5.5 Dr Reddy?s Key News & Latest Developments
7.6 Celgen Biopharma
7.6.1 Celgen Biopharma Company Summary
7.6.2 Celgen Biopharma Business Overview
7.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Major Product Offerings
7.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.6.5 Celgen Biopharma Key News & Latest Developments
7.7 Cadila Healthcare
7.7.1 Cadila Healthcare Company Summary
7.7.2 Cadila Healthcare Business Overview
7.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Major Product Offerings
7.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.7.5 Cadila Healthcare Key News & Latest Developments
7.8 Hisun Pharma
7.8.1 Hisun Pharma Company Summary
7.8.2 Hisun Pharma Business Overview
7.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Major Product Offerings
7.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.8.5 Hisun Pharma Key News & Latest Developments
7.9 Torrent Pharmaceuticals
7.9.1 Torrent Pharmaceuticals Company Summary
7.9.2 Torrent Pharmaceuticals Business Overview
7.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Major Product Offerings
7.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales and Revenue in Global (2018-2023)
7.9.5 Torrent Pharmaceuticals Key News & Latest Developments
8 Global Biosimilar Monoclonal Antibodies Production Capacity, Analysis
8.1 Global Biosimilar Monoclonal Antibodies Production Capacity, 2018-2029
8.2 Biosimilar Monoclonal Antibodies Production Capacity of Key Manufacturers in Global Market
8.3 Global Biosimilar Monoclonal Antibodies Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Biosimilar Monoclonal Antibodies Supply Chain Analysis
10.1 Biosimilar Monoclonal Antibodies Industry Value Chain
10.2 Biosimilar Monoclonal Antibodies Upstream Market
10.3 Biosimilar Monoclonal Antibodies Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Biosimilar Monoclonal Antibodies Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer